Brief: Merck To Acquire Cidara Therapeutics, Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

Cidara Therapeutics

14/11/2025 11:48

Nov 14 (Reuters) - Merck & Co Inc MRK.N:

MERCK TO ACQUIRE CIDARA THERAPEUTICS, INC., DIVERSIFYING ITS PORTFOLIO TO INCLUDE LATE-PHASE ANTIVIRAL AGENT

MERCK & CO INC - TO BUY CIDARA FOR $9.2 BILLION

MERCK & CO INC PROPOSED DEAL FOR $221.50 PER SHARE IN CASH

MERCK & CO INC: UNDER TERMS OF MERGER AGREEMENT, MERCK, THROUGH A UNIT, WILL ACQUIRE ALL OF OUTSTANDING SHARES OF CIDARA

Source text: ID:nBw1hzDwPa

Further company coverage: MRK.N

 ((Reuters.Briefs@thomsonreuters.com;))